1. Pink Sheet
  2. >>Market Access

Medicare Price Negotiation Law Fixes Face ‘Big Problem,’ Former Trump Official Says

 
• By Cathy Kelly

Health policy experts and biopharma supply chain stakeholders discuss prospects for legislation reforming the Inflation Reduction Act, pharmacy benefit manager practices, and the 340B program during a recent conference.

Will Republican Focus On US Government Spending Cuts Hamper IRA Fixes? • Source: Shutterstock

Efforts to amend the Inflation Reduction Act to narrow the types of drugs subject to the law’s Medicare price negotiation program may have trouble succeeding in a political environment that will be increasingly focused on cutting spending, according to former Trump Administration official Joe Grogan.

Key Takeaways

  • Legislative relief from Medicare negotiation for small molecule and orphan drugs may be increasingly challenging.

Grogan, who served as director of the White House Domestic Policy Council and associate director for health programs at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Sponsors Asked, EMA Delivered: One Handbook To Navigate CTIS

 
• By Vibha Sharma

The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.

Will Tidmarsh’s Industry Experience Translate As US FDA’s Chief Drug Regulator?

 
• By Sarah Karlin-Smith and Derrick Gingery

The long-time industry executive led several drug approvals but may have a lot to learn about the intimate details of application review and the Center for Drug Evaluation and Research.

Don’t Look Back: US FDA AdComm Offers No Flexibility For Rexulti’s Post Hoc Bid In PTSD

 
• By Bridget Silverman

The US FDA's Psychopharmacology Advisory Committee emphasized high standards over regulatory flexibility while turning down Otsuka's brexpiprazole plus serotonin for post-traumatic stress disorder based on conflicting Phase III trials and post-hoc Phase II analyses.